文献速递糖尿病肥胖与代谢综合征

肝脏PDIA5通过稳定ATF6改善高血糖与胰岛素抵抗

Hepatic PDIA5 improves hyperglycaemia and insulin resistance through stabilisation of ATF6.
PubMed 文献 · Diabetologia · 2026-09-17

本研究探讨PDIA5在肝脏糖代谢中的作用。在MASLD患者和糖尿病小鼠中肝脏PDIA5表达降低,过表达PDIA5可抑制糖异生基因表达、改善高血糖和胰岛素敏感性;机制上PDIA5与ATF6互作并阻止其泛素化降解,从而抑制糖异生。

要点

  • 肝脏PDIA5表达在MASLD患者和糖尿病小鼠中显著降低。
  • 过表达PDIA5抑制Pck1和G6pc1表达、减少肝糖输出并改善高血糖。
  • PDIA5通过拮抗SYVN1介导的泛素化稳定ATF6,增强肝脏胰岛素敏感性。

核心结论

  • 研究识别出PDIA5-SYVN1-ATF6调控轴对维持肝脏葡萄糖稳态至关重要,PDIA5是连接肝脏脂质过载与糖代谢紊乱的分子检查点及2型糖尿病潜在治疗靶点。

研究设计与样本

  • 研究评估了MASLD患者肝活检样本和2型糖尿病小鼠模型中肝脏PDIA5表达。
  • 通过腺病毒介导的肝脏过表达在HFD喂养雄性小鼠和原代小鼠肝细胞中研究PDIA5功能。
  • 利用葡萄糖、胰岛素和丙酮酸耐量试验及高胰岛素-正葡萄糖钳夹表征代谢表型。
  • 在MPHs和HEK293T细胞中采用免疫共沉淀、泛素化实验和染色质免疫沉淀解析PDIA5-ATF6信号轴。
  • 使用全身Pdia5敲除雄性小鼠和腺病毒介导的肝脏特异性Pdia5缺陷雌性小鼠确认PDIA5的生理必要性。

主要发现

  • MASLD患者和糖尿病小鼠肝脏PDIA5表达显著降低。
  • HFD喂养小鼠肝脏过表达PDIA5通过抑制糖异生基因Pck1和G6pc1表达及葡萄糖生成改善高血糖和葡萄糖稳态。
  • PDIA5与内质网应激感受器ATF6物理互作并稳定ATF6,阻止E3泛素连接酶SYVN1对ATF6的泛素化及蛋白酶体降解。
  • ATF6稳定减弱共激活因子CRTC2在糖异生启动子上的募集并抑制PERK-TRB3信号轴,增强肝脏胰岛素敏感性。
  • ATF6敲低消除PDIA5对糖代谢的保护作用;Pdia5基因缺失加剧HFD喂养小鼠的葡萄糖不耐受。

临床怎么用

  • PDIA5-SYVN1-ATF6轴可作为2型糖尿病肝脏糖异生靶向干预的潜在方向。
  • 增强肝脏PDIA5/ATF6信号可能改善高血糖和胰岛素抵抗,但需进一步临床验证。

局限性

  • 研究主要基于小鼠模型和细胞实验,人体因果证据有限。
  • PDIA5过表达采用腺病毒载体,长期安全性和可行性未评估。
  • MASLD患者肝脏PDIA5表达降低的样本量和人群特征未在摘要中详述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Dysregulation of hepatic glucose production, primarily driven by aberrantly elevated gluconeogenesis, is a core pathological feature of type 2 diabetes. However, the molecular mechanisms governing this process remain incompletely understood. Protein disulfide isomerase A5 (PDIA5) is ubiquitously expressed, but its specific function in hepatic metabolism is unknown. We hypothesised that PDIA5 plays a critical role in regulating hepatic gluconeogenesis, and that its dysregulation contributes to hyperglycaemia. METHODS: We assessed hepatic PDIA5 expression in liver biopsies from individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and from mouse models of type 2 diabetes. The function of PDIA5 was investigated using adenoviral-mediated overexpression in the livers of male mice fed a high-fat diet (HFD) and in mouse primary hepatocytes (MPHs). Metabolic phenotypes were characterised through glucose, insulin and pyruvate tolerance tests and hyperinsulinaemic-euglycaemic clamps. Mechanistic investigations in MPHs and HEK293T cells, involving co-immunoprecipitation, ubiquitination assays and chromatin immunoprecipitation, were used to delineate the PDIA5-ATF6 (activating transcription factor 6) signalling axis. The physiological necessity for PDIA5 was confirmed using whole-body Pdia5 knockout male mice and adenovirus-mediated liver-specific Pdia5-deficient female mice. RESULTS: Hepatic PDIA5 expression was significantly reduced in both individuals with MASLD and diabetic mice. Hepatic overexpression of PDIA5 in HFD-fed mice ameliorated hyperglycaemia and improved glucose homeostasis by suppressing expression of gluconeogenic genes (Pck1 and G6pc1) and glucose production. Mechanistically, PDIA5 was found to physically interact with and stabilise the endoplasmic reticulum stress sensor ATF6, which is a known suppressor of gluconeogenesis. PDIA5 shields ATF6 from the E3 ubiquitin ligase synoviolin 1 (SYVN1), thereby inhibiting its ubiquitination and subsequent proteasomal degradation. This stabilisation of ATF6 attenuated recruitment of the co-activator CRTC2 to gluconeogenic promoters and suppressed the PERK-TRB3 signalling axis, enhancing hepatic insulin sensitivity. Importantly, knockdown of ATF6 abolished the protective effects of PDIA5 on glucose metabolism. Conversely, genetic deletion of Pdia5 exacerbated glucose intolerance in HFD-fed mice. CONCLUSIONS/INTERPRETATION: Our findings identify a novel PDIA5-SYVN1-ATF6 regulatory axis that is crucial for maintaining hepatic glucose homeostasis. These results establish PDIA5 as a critical molecular checkpoint linking hepatic lipid overload to glucose dysregulation, and highlight it as a potential therapeutic target for type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Wan J, Zhang M, Ma T, et al. Hepatic PDIA5 improves hyperglycaemia and insulin resistance through stabilisation of ATF6. Diabetologia. 2026. PMID: 42752965. doi:10.1007/s00125-026-06862-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。